Literature DB >> 17674917

Combined 5-fluorouracil, low-molecular-weight heparin, and silicone oil in the management of complicated retinal detachment with proliferative vitreoretinopathy grade C.

Reinaldo A Garcia1, Juan G Sanchez, J Fernando Arevalo.   

Abstract

BACKGROUND AND
OBJECTIVE: To determine whether combined 5-fluorouracil (5-FU) and low-molecular-weight heparin (LMWH) could improve the outcome of vitreoretinal surgery with silicone oil for the management of complicated retinal detachment with proliferative vitreoretinopathy (PVR) grade C. PATIENTS AND METHODS: In an interventional, controlled, nonrandomized clinical trial, 33 eyes with complicated retinal detachment and PVR underwent vitrectomy with silicone oil and perioperative infusion of 5-FU and LMWH (study group) and 31 eyes underwent vitrectomy with silicone oil without adjunctive medication (control group).
RESULTS: In the study group, 24 eyes (72.7%) had the retina attached and 9 had a retinal redetachment (27.3%) at 6 months. In the control group, 25 eyes (80.6%) had the retina attached and 6 eyes (19.4%) had a retinal redetachment at 6 months (chi-square: 0.53, P > .05). One-year postoperative data were available for 17 eyes in the study group and 19 eyes in the control group. Four eyes in each group (23.5% and 21%, respectively) developed retinal redetachment (chi-square: 0.03, P > .05).
CONCLUSIONS: Combined 5-FU and LMWH does not seem to improve the outcome of vitreoretinal surgery with silicone oil for the management of complicated retinal detachment with PVR grade C.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17674917     DOI: 10.3928/15428877-20070701-02

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  7 in total

Review 1.  [Pharmacological approach to treatment of proliferative vitreoretinopathy].

Authors:  C S Priglinger; S Priglinger
Journal:  Ophthalmologe       Date:  2013-10       Impact factor: 1.059

2.  5-Fluoro-Uracil and Low Molecular Weight Heparin in the Management of Proliferative Vitreo-retinopathy.

Authors:  V S Gurunadh; A Banarji; S Patyal; T S Ahluwalia; A K Upadhyay; M Bhadauria
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  A novel cytarabine crystalline lipid prodrug: hexadecyloxypropyl cytarabine 3',5'-cyclic monophosphate for proliferative vitreoretinopathy.

Authors:  Jae Suk Kim; James R Beadle; William R Freeman; Karl Y Hostetler; Kathrin Hartmann; Nadejda Valiaeva; Igor Kozak; Laura Conner; Julissa Trahan; Kathy A Aldern; Lingyun Cheng
Journal:  Mol Vis       Date:  2012-07-14       Impact factor: 2.367

4.  Antiproliferative property of hexadecyloxypropyl 9-[2-(phosphonomethoxy) ethyl] guanine (HDP-PMEG) for unwanted ocular proliferation.

Authors:  Jiangping Hou; Yuli Li; Zhonglou Zhou; Nadejda Valiaeva; James R Beadle; Karl Hostetler; William R Freeman; Dan-Ning Hu; Hao Chen; Lingyun Cheng
Journal:  Mol Vis       Date:  2011-03-02       Impact factor: 2.367

5.  Doxycycline Ameliorates the Severity of Experimental Proliferative Vitreoretinopathy in Mice.

Authors:  Shun-Hua Chen; Yu-Jheng Lin; Li-Chiu Wang; Hsien-Yang Tsai; Chang-Hao Yang; Yu-Ti Teng; Sheng-Min Hsu
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

6.  Combined 5-Fluorouracil and Low Molecular Weight Heparin for the Prevention of Postoperative Proliferative Vitreoretinopathy in Patients With Retinal Detachment: A Meta-Analysis.

Authors:  Chen Chen; Peng Chen; Xia Liu; Hua Li
Journal:  Front Med (Lausanne)       Date:  2021-11-30

7.  Tug of war: A bimanual technique for anterior circumferential proliferative vitreoretinopathy in recurrent retinal detachment.

Authors:  Daraius Shroff; Indranil Saha; Gagan Bhatia; Ranjan Dutta; Charu Gupta; Cyrus M Shroff
Journal:  Indian J Ophthalmol       Date:  2020-10       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.